iiinova — where your digital self keeps evolving

Reposted by Jennifer A. Marks, MD

D. Ross Camidge @drcamidge.bsky.social · 22/02/2026

At last week’s lung cancer conference I went full public with my dual role as patient and expert. I spoke after Jane Perlmutter a four time survivor (middle). Both of us were introduced by Dr Shirish Gadgeel- Jane’s doctor and my friend.

1102

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 21/01/2026

New lung cancer research insights 🎥 In this expert roundtable led by Dr. @jennifermarksmd, Dr. Elliot Brea shares ASCO 2025 updates on emerging cellular therapies, including CAR T-cell therapy, for NSCLC and SCLC—explained clearly and concisely. Watch the full video: youtu.be/hLy10mitvG8

022

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 08/12/2025

Great to share lung cancer research updates with colleagues and friends at the 2025 IASLC NACLC meeting Thank you to chairs Drs. Bestvina, Marrone, Rengan and Gillaspie for organizing an energizing and fun conference @iaslc.bsky.social @danafarber.bsky.social #NACLC25

182

Reposted by Jennifer A. Marks, MD

D. Ross Camidge @drcamidge.bsky.social · 08/09/2025

After three years I feel ready to enter a new phase of patient empowerment by publicly disclosing my own disgnosis. This went live today and all good. news.cuanschutz.edu/cancer-cente...

news.cuanschutz.edu

World Lung Cancer Expert Diagnosed with Advanced Lung Cancer

D. Ross Camidge, MD, PhD, has spent his career fighting lung cancer. In 2022, that fight turned personal when he received a diagnosis of his own.

102710

Reposted by Jennifer A. Marks, MD

BK. Titanji @boghuma.bsky.social · 11/07/2025

Rolling back vaccine access while expanding unwarranted access to over the counter ivermectin is proof that we are living in a most idiotic timeline.

2721649

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 04/04/2025

A season of celebration - huge congratulations to superstar mentees who will be moving on to new adventures, including UCLA med and Harvard med!! The future is bright!

142

Reposted by Jennifer A. Marks, MD

Estelamari Rodríguez @latinamd.bsky.social · 07/04/2025

#ASCOAdvocacySummit starting today with remarks by @RepHerbConaway MD. Honored to be here representing FL oncologists to advocate for issues that impact our patients and field. #patientadvocacy @ascocancer.bsky.social @sylvestercancer

021

Reposted by Jennifer A. Marks, MD

Yvonne Diaz @yvonnediaz.bsky.social · 16/03/2025

We patients often wonder why each of us responds so individually to our targeted therapies. It’s heartbreaking when you see up close how not all derive the same benefit from the exact same drug w seemingly the same disease. Important to understand what factor influence this & do something about it.

031

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Dr. @LeXiuning now presenting #EGFR and #HER2 targeted therapies -new development and changing landscapes at our Targeted Therapies in Lung Cancer Live event! #TargetedTherapies #LungCancer #Flaura2 #Osimeritinib

022

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

• If you smoke, quit. Your risk of cancer starts coming down about two years. • Quitting is hard…..so try again! • Nicotine replacement (gum, patches, or vape) is better than smoking. Amazing presentation Dr. Jorge Nieva!

022

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Dr. Jorge Nieva now presenting #KRAS and #BRAF. What is signaling? Why do mutations in KRAS and BRAF mess it up? #TargetedTherapiesInLungCancer #LungCancer

021

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Amazing presentation of Dr. @ADesaiMD about NTRK (Neurotrophic Tyrosine Receptor Kinase). Join us now at live.classy.org/register/ttl... #MET #NTRK #NRG1 #NSCLC

021

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Happening now! Dr. Aakash Desai, MD, MPH talking about MET, NTRK and NRG1 driven NSCLC. What is #MET?

032

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

What is Rearranged during Transfection? By Dr. @ChristineBestv1 at our Targeted Therapies in Lung Cancer Event. #RET #LungCancer #TargetedTherapies #RETFussion

042

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Dr. @ChristineBestv1 now presenting: ALK, ROS1 and RET: Pushing the Boundaries of Targeted Therapies #ALK #ROS1 #RET #LungCancer #TargetedTherapies #cancerGRACE

186

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Q&A session with Drs. @lungoncdoc, @MMarmarelis, @LudaBazhenovaMD, and @IyengarPuneeth Is it better to continue on the same therapy as long as possible? #TargetedTherapiesInLungCancer #LungCancer

054

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Dr. Puneeth Iyengar presenting live the Role of Radiation in Patients with Oncogenic Drivers. Click here to join us: live.classy.org/register/ttl...

042

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

What types of Targeted Therapies are there for NSCLC patients? By Dr. Melina Marmarelis #LungCancer #TargetedTherapiesinLungCancer #NSCLC

032

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Dr. Eric Singhi now live, presenting Understanding Resistance to Targeted Therapy in Non-Small Cell Lung Cancer. #TargetedTherapies #LungCancer #MolecularTesting #PersonalizedTreatment #NSCLC

052

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

What are some treatment strategies at time of progression? - Ask about Clinical Trials - Try to target specific mechanisms of resistance - "Standard of care" options Always advocated for yourself. Dr. Eric Singhi #LungCancerAdvocates #CancerCare #LungCancer #ClinicalTrials #Chemotherapy

042

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

What is cancer? By Dr. Triparna Sen #LungCancer #TargetedTherapies #TriparnaSen #CancerGRACE

021

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Dr. Melina Marmarelis presenting: What is Targeted Therapy? #TargetedTherapiesinLungCancer #LungCancer

032

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Dr. Karen Yun presenting: How Do You Read a Molecular Testing Report? What are Driver Alterations in Lung Cancer? #TargetedTherapiesInLungCancer #LungCancer #ALK #ROS1 #RET #NTRK #EGFR #BRAF #MET #HER2 #KRAS

074

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Next Generation Sequencing provides a comprehensive profile of tumor genetics. What are the pros and cons of #NGS? Join us at our Targeted Therapies in Lung Cancer If you want to learn more about NGS. We are live now! give.cancergrace.org/event/target...

032

Reposted by Jennifer A. Marks, MD

cancergrace @cancergrace.bsky.social · 15/03/2025

Now Dr. Jennifer Marks presenting Biomarker Testing 101 for Lung Cancer at our Targeted Therapies in Lung Cancer. What is a #biomarker? #ALk #ROS1 #LungCancer #TargetedTherapies #cancerGRACE #CancerEducation

021

Reposted by Jennifer A. Marks, MD

Yvonne Diaz @yvonnediaz.bsky.social · 15/03/2025

Great fishing 🎣 analogy from Dr @ludabazhenovamd.bsky.social on the use of liquid biopsies at the @cancergrace.bsky.social Patient Forum: If a liquid biopsy doesn’t turn up any biomarkers it doesn’t mean there aren’t any fish in the sea. Important to continue w tissue testing. #LCSM

052

Reposted by Jennifer A. Marks, MD

Jack West, MD, FASCO @jackwestmd.bsky.social · 15/03/2025

I didn't know Dr. Yun before today, but she raised at UCSD with Drs. Luda Bazhenova & Sandip Patel. She did a great job. Looking forward to seeing her career trajectory.

142

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 14/03/2025

Outstanding and inspiring talk by Dr Alice Shaw on 20+yr of multidisciplinary scientific collaborations to develop effective therapies for ALK+ lung cancers at the DFCI CCG Symposium @danafarber.bsky.social #lcsm #oncsky

031

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 12/03/2025

“As physicians, we are committed to finding treatments and cures. While we recognize the importance of directing more funding toward direct research costs, this policy carries unintended consequences that threaten the sustainability of U.S. biomedical research.”

022

Reposted by Jennifer A. Marks, MD

Tom Newsom-Davis @tnewsomdavis.bsky.social · 03/03/2025

Fantastic discussion of biomarkers for ADCs from Jan von der Thüsen 🔹 ORR with ADCs very variable 🔹 Relying on IHC may be problematic 🔹 Is a biomarker agnostic approach reasonable? 🔹 Could NMR be a solution, but it has its own challenges

073

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 22/02/2025

Excellent summary of targeted therapies in clinical trials for mesothelioma, a thoracic malignancy without approved targeted agents by Dr Melina Marmarelis #TTLC25 @iaslc.bsky.social #lcsm

011

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 22/02/2025

Dr Mehmet Altan presenting on targeted therapies in clinical trials for thymic malignancies, emphasizing the importance of multicenter collaboration in this cancer #TTLC25 #lcsm @iaslc.bsky.social

011

Reposted by Jennifer A. Marks, MD

Gregory Riely @rielymd.bsky.social · 22/02/2025

Great talk by @jia-luo.bsky.social from @danafarber.bsky.social at #TTLC25 talking about NUT carcinoma also highlights recent review www.nature.com/articles/s41...

122

Reposted by Jennifer A. Marks, MD

Gregory Riely @rielymd.bsky.social · 22/02/2025

Important poster presented at #TTLC25 by @jessieross.bsky.social and Alissa Cooper from @mskcancercenter.bsky.social on overlap of DLL3/SEZ6 in high grade neuroendocrine cancers

0144

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 22/02/2025

Excellent talk and framework on the approach to targeted therapies for neuroendocrine tumors by Dr Nathaniel Myall #TTLC25 #lcsm @iaslc.bsky.social

031

Reposted by Jennifer A. Marks, MD

D. Ross Camidge @drcamidge.bsky.social · 21/02/2025

Targeted Therapies of Lung Cancer meeting 2025. Huntington Beach, California. Fish are fun, cherubs are wierd

1112

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 20/02/2025

Packed room at #TTLC25 and fantastic intro talk to EGFR therapy sequencing and unanswered questions by my colleague Dr Julia Rotow #lcsm #oncsky @danafarber.bsky.social @iaslc.bsky.social

173

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 20/02/2025

Excellent summary of the approach to uncommon EGFR mutations by Dr Xiuning Le (MDACC) #TTLC25 #lcsm #oncsky @iaslc.bsky.social

041

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 21/02/2025

Fantastic comprehensive talk on role of consolidative radiation in lung cancer treatment by colleague Dr David Kozono Great discussion regarding existing data including PORT and ongoing trials - and subsequent Q&A! @danafarber.bsky.social #lcsm #oncsky @iaslc.bsky.social

032

Reposted by Jennifer A. Marks, MD

JAMA @jama.com · 13/02/2025

🧵 US states that implemented abortion bans saw higher than expected infant mortality rates, with larger increases among Black infants and those in southern states, according to this analysis of US national vital statistics data from 2012–2023. ja.ma/4aVchPn #MedSky

Figure 1. Trends in Biannual US Infant Mortality Rates, 2012-2023

11340247

Reposted by Jennifer A. Marks, MD

Tara Herrmann, PhD @tlblase.bsky.social · 03/02/2025

My philosophy for the upcoming years Darkness grows in the quiet

0106

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 04/02/2025

4/ WHY? 🧬We now know NUT carcinoma, defined by NUTM1 gene fusions w/ BRD4/3/2, NSD3, or ZNF532 (and *not* to be confused with other NUTM1 rearranged cancers), almost always presents as poorly differentiated/ squamous carcinoma of lung 🫁/ head/neck 🗣️ primary www.sciencedirect.com/science/arti...

Characteristics of NUTM1-rearranged cancers, The NUTM1 fusion oncoprotein complex. Top, a variety of NUTM1fusion partners encode proteins that either contain BRD4, or that bind BRD4,thus the various NUT fusion proteins are interchangeable in that they all form anoncogenic complex containing the same protein constituents. The frequencies ofeach NUTM1 fusion shown are based on the largest single series (n = 127)8. Bottom,this complex creates large super-enhancers via increased histone H3 lysine 27acetyltransferase activity mediated by the p300–NUT complex interaction.Enrichment of super-enhancer regions with acetyl histone H3 lysine 27 drivesexpression of MYC and other oncogenic genes, such as SOX2 and TP63, by increasingpromoter–enhancer contacts that activate transcription. EZH2 expression isupregulated in NUT carcinomas, probably via upregulation of EZH2 transcription byMYC. Increased expression of EZH2 results in transcriptional downregulation of thetumour-suppressor gene CDKN2A through trimethylation of histone H3 lysine 27(H3K27me3). Ac, acetylated lysine residue; C/H, cysteine and histidine; ET domain,extraterminal domain; NES, nuclear export signal; NLS, nuclear localization signal;PHD, plant homeodomain (PHD) zinc finger domain; PWWP, Pro–Trp–Trp–Prodomain; SET, Su(var)3-9, Enhancer-of-zeste and Trithorax domain.

111

Reposted by Jennifer A. Marks, MD

Jia Luo, MD @jia-luo.bsky.social · 04/02/2025

🌟 In Nature Reviews Clinical Oncology, we examine the *overwhelming* evidence for classifying NUT carcinoma as a subtype of squamous lung cancer and squamous head and neck cancer 🫁 🗣️ rdcu.be/d8uni @natrevclinoncol.bsky.social #medsky #oncsky #meded #lcsm #lungcancer 🧵 Highlights:

Jia Luo 1,2 , Justin A. Bishop3, Steven G. DuBois4, Glenn J. Hanna1,2, Lynette M. Sholl 5, Edward B. Stelow6,Lester D. R. Thompson7, Geoffrey I. Shapiro 1,2 & Christopher A. French 5

Abstract

In the past two decades, treatment for non-small-cell lung cancers(NSCLCs) and head and neck squamous cell carcinoma (HNSCC) hasadvanced considerably, owing largely to the characterization of distinctoncological subtypes, the development of targeted therapies for eachsubtype and the advent of immunotherapy. Data emerging over thepast two decades suggest that NUT carcinoma, a highly aggressivemalignancy driven by a NUT fusion oncoprotein and arising in the lungs,head and neck, and rarely in other sites, is a squamous cell carcinoma(SCC) based on transcriptional, histopathological, cell-of-origin andmolecular characteristics. NUT carcinoma has an estimated incidenceof 1,400 cases per year in the United States, surpassing that of somerare NSCLC and HNSCC subtypes. However, NUT carcinoma is currentlynot recognized as an SCC of the lungs or head and neck. The orphanclassification of NUT carcinoma as a distinct entity leads to a lack ofawareness of this malignancy among oncologists and surgeons, despiteearly diagnosis being crucial for this cancer type with a median survivalof only ~6.5 months. Consequently, NUT carcinoma is underdiagnosedand often misdiagnosed, resulting in limited research and progress indeveloping effective treatments in one of the most aggressive formsof lung and head and neck cancer. With a growing number of targetedagents that can potentially be used to treat NUT carcinoma, improvedrecognition through reclassification and inclusion of NUT carcinomaas a squamous NSCLC or an HNSCC when arising in these locations willaccelerate the development of effective therapies for this disease. Thus,in the Perspective, we propose such a reclassification of NUT carcinomaas an SCC and discuss the supporting evidence.

183